Andrew Gengos

Andrew W.
Gengos is currently Director at Turn Therapeutics (TM), Inc., Independent Director at Turn Therapeutics, Inc. since 2020, Director at Seneca Therapeutics, Inc. starting 2025, and Chief Financial Officer & Treasurer at Immuneering Corp.
starting 2026.
Former positions include President, Chief Executive Officer & Director at ImmunoCellular Therapeutics Ltd. from 2012 to 2016; President, Chief Executive Officer & Director at Neuraltus Pharmaceuticals, Inc. from 2010 to 2012; Vice President-Strategy & Corporate Development at Amgen, Inc. from 2002 to 2010; Senior Manager-Engagement at McKinsey & Co., Inc. from 1991 to 1998; Chief Business Officer at Cyteir Therapeutics, Inc. from 2020 to 2023; COO & Head-Corporate Development at Synlogic, Inc. from 2017 to 2018; Chief Financial & Business Officer at AOBiome Therapeutics, Inc. in 2019; Chief Financial & Business Officer at LeonaBio, Inc. from 2023 to 2024; Chief Financial & Accounting Officer at Terns Pharmaceuticals, Inc. from 2025 to 2026; Vice President-Strategy & Development at Chiron Corp.
in 2010; Vice President-Strategy & Corporate Development at Relypsa, Inc. in 2010; Director at Allozyne, Inc.; Chief Financial & Business Officer at Dynavax Technologies Corp.
The education history includes undergraduate studies at Massachusetts Institute of Technology and an MBA from UCLA Anderson School of Management.